Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation

Background. Despite afatinib as a new first-line treatment for EGFR L858R and exon 19 deletion or other rare EGFR-mutation patients, the acquired resistance or toxic effects associated with it limited its use clinically. The controlling of acquired resistance or optimization of the afatinib dosage i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuehui, Huang, Chaoyuan, Cui, Biyu, Pang, Yebin, Liang, Rong, Luo, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168479/
https://www.ncbi.nlm.nih.gov/pubmed/34122668
http://dx.doi.org/10.1155/2021/5530673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168479/
https://www.ncbi.nlm.nih.gov/pubmed/34122668
http://dx.doi.org/10.1155/2021/5530673

Ejemplares similares